London, UK, 13 August 2012 - Lombard Medical Technologies PLC(AIM: LMT), the specialist medical technology company focussed on innovative vascular products, will announce its interim results for the six months ended 30 June 2012 on Thursday 30 August 2012.
- Ends -
For further information:
Lombard Medical Technologies PLC
Tel: +44 (0)1235 750 800
Simon Hubbert, Chief Executive Officer
Ian Ardill, Chief Financial Officer
Canaccord Genuity Limited
Tel : +44 (0)20 7523 8000
Jamie Adams / Mark Dickenson / Lucy Tilley
Tel: +44 (0)20 7831 3113
Simon Conway / Susan Stuart
About Lombard Medical
Lombard Medical Technologies PLC (AIM: LMT), is a medical device company focused on device solutions for the $1.2 billion dollar per annum abdominal aortic aneurysm (AAA) repair market. AAAs are a balloon-like enlargement of the aorta which, if left untreated, may rupture and cause death. Approximately 4.5 million people are living with AAAs in the developed world and each year 600,000 new cases are diagnosed. The market for endovascular stent grafts for this application is expected to grow to $1.6 billion by 2015. The Company's lead product, Aorfix™, is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy which is often present in advanced AAA disease. Aorfix™ is currently being commercialised in the EU, and has been submitted to the FDA for approval in the U.S.
The Company is headquartered in Oxfordshire, with operations in Ayrshire and Phoenix, USA.
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.